Global Health & Medicine, Год журнала: 2024, Номер 6(6), С. 404 - 415
Опубликована: Май 22, 2024
Hepatitis B and C (HBV HCV) testing has been performed in Japan since 2002 is subsidized by central prefectural governments. A follow-up program for HBV- or HCV-infected persons was started at that time Ishikawa Prefecture. This study analyzed the long-term data from this program. In total, 1029 participants Follow-up Program (HBV-infected,
Язык: Английский
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(20), С. 11213 - 11213
Опубликована: Окт. 18, 2024
Liver inflammation is frequently linked to oxidative stress and dysregulation of bile acid fatty metabolism. This review focuses on the farnesoid X receptor (FXR), a critical regulator homeostasis, its interaction with nuclear factor erythroid 2-related 2 (Nrf2), key modulator cellular defense against stress. The explores interplay between FXR Nrf2 in liver inflammatory diseases, highlighting potential therapeutic effects natural agonists. Specifically, compounds such as auraptene, cafestol, curcumin, fargesone A, hesperidin, lycopene, oleanolic acid, resveratrol, rutin, ursolic withaferin A are reviewed for their ability modulate both pathways. article discusses alleviate inflammation, stress, damage diseases metabolic-associated disease (MAFLD), cholestatic injury, viral hepatitis. In addition, we address molecular mechanisms driving including immune responses, accumulation, while also summarizing relevant experimental models. emphasizes promising targeting pathways using compounds, paving way future treatments diseases. Finally, limitations clinical application were indicated, further research directions proposed.
Язык: Английский
Процитировано
12
Hepatology International, Год журнала: 2025, Номер unknown
Опубликована: Янв. 11, 2025
Liver cancer (LC) is a major concern in the Asia-Pacific region, particularly China, Korea, and Japan. In this study, we aimed to investigate burden, trends, predictions related LC these countries. Using data from Global Burden of Disease Study 2021, epidemiological characteristics [incidence, deaths, disability-adjusted life-years (DALYs)] for were analysed stratified by specific etiologies Japan, South Korea. We examined temporal trends burden over last 32 years projected changes following 25 years. The risk factors associated with deaths DALYs also investigated. highest LC-related incidence, mortality, recorded China (196,637 incidents, 172,068 mortalities, 4,890,023 DALYs), lowest Korea (18,642 13,674 326,336 DALYs). age-standardized rates (ASRs) (19.94 per 100,000, 14.53 354.57 100,000), Japan (9.89, 7.29, 145.74, respectively). From 1990 incidents three countries increased, ASRs decreased. caused five increased past years, non-alcoholic steatohepatitis (NASH) was largest increasing China. Infections hepatitis B virus remained leading cause while C prevailing High body mass index (BMI) most sharply factor Alcohol drug use main respectively. rise steadily between 2022 2046. remains significant disease now next Regarding factors, NASH high BMI alcohol should receive attention.
Язык: Английский
Процитировано
2
EClinicalMedicine, Год журнала: 2024, Номер 73, С. 102671 - 102671
Опубликована: Май 30, 2024
BackgroundIt is unclear whether direct-acting antivirals (DAAs) treatment improves the disease burden in hepatitis C virus (HCV) infection. This study aimed to investigate effect of DAA on reduction patients with HCV infection using individual participant data.MethodsThis nationwide multicentre retrospective cohort recruited from 29 tertiary institutions South Korea. The data collection was done medical records each institution. included untreated and DAAs-treated excluded those a history interferon-based treatments. Disease primary outcome, as represented by disability-adjusted life years (DALYs). Improvement fibrosis after assessed APRI, FIB-4 index, liver stiffness (LS) transient elastography. Clinical outcomes were hepatocellular carcinoma (HCC), decompensation, mortality.FindingsBetween January 1, 2007, February 17, 2022, 11,725 infection, 8464 (72%) whom treated DAAs, analysed. significantly improved APRI- (median 0.64 [interquartile range (IQR), 0.35–1.31]–0.33 [0.23–0.52], p < 0.0001), FIB-4- 2.42 [IQR, 1.48–4.40]–1.93 [1.31–2.97], LS-based 7.4 5.3–12.3]–6.2 [4.6–10.2] kPa, 0.0001). During median follow-up period 27.5 months (IQR, 10.6–52.4), 469 died (4.0%), 586 (5.0%) developed HCC, 580 (4.9%) decompensation. APRI-based DALY estimate lower group than 4.55 vs. 5.14 years, FIB-4-based 5.43 3.00–6.44] 5.79 [3.85–8.07] differences between groups greatest aged 40–60 years. In multivariable analyses, had reduced risk mortality compared (hazard ratios: 0.41 [95% confidence interval (CI), 0.34–0.48], 0.31 CI, 0.30–0.38], 0.22 0.17–0.27], respectively; 0.0001).InterpretationOur findings suggest that associated improvement liver-related fibrosis-based However, further studies biopsy are needed clarify exact beyond noninvasive tests.FundingThe Korea Control Prevention Agency.
Язык: Английский
Процитировано
4
Journal of Hepatology, Год журнала: 2024, Номер unknown
Опубликована: Сен. 1, 2024
Язык: Английский
Процитировано
4
Сибирский научный медицинский журнал, Год журнала: 2025, Номер 45(1), С. 6 - 14
Опубликована: Фев. 25, 2025
The objective of the review is to systematize current information on prevalence viral hepatitis B and C, risks hepatocellular carcinoma (HCC) against their background methods its treatment prevention. highest HCC observed in countries Southeast Asia, which agrees with C these regions, as well peculiarities nutrition. It has been noted that increased alcohol consumption metabolic syndrome are also risk factors for patients or C. When diagnosed early stages, treatable locoregional techniques including surgical resection, radiofrequency ablation, transarterial chemoembolization, liver transplantation. Methods preventing development include a healthy lifestyle, avoidance bad habits, monitoring condition if patient hepatitis. Timely vaccination correct expected reduce number HCC. Universal screening virus infection among adults aged 18–69 years cost-effective. Standardization diagnosis implementation surveillance programs at-risk individuals critical earlier diagnosis. Future efforts should focus expanding our knowledge causes HCC, identifying highly specific biomarkers, developing more effective treatments.
Язык: Английский
Процитировано
0
BMC Public Health, Год журнала: 2025, Номер 25(1)
Опубликована: Апрель 3, 2025
Viral hepatitis, recognized as a significant global public health threat by the World Health Organization (WHO), has spurred efforts to establish elimination goals 2030. In Republic of Korea (Korea), prevalence Hepatitis C virus (HCV) infection exhibits regional disparities, necessitating tailored control measures at level. This study aimed analyze HCV trend area (region/town) in Korea, from 2005 2022, and identify areas requiring priority management. A comprehensive analysis trends across different geographical regions towns 2022 was conducted. Using data National Insurance Service, individuals diagnosed with acute or chronic during this period were included analysis. adjusted area, year, sex, age. Additionally, annual percent changes (APC) average APC (AAPC) examined using Joinpoint regression Age, region per 100,000 people declined 151 98 2022. During 18 years, highest recorded southern (Busan, Jeonnam, Gyeongnam) Namhae-gun Gyeongnam, Boeun-gun Chungbuk, Sunchang-gun Jeonbuk. The age-, sex-, region-adjusted decreased significantly an -2.5% (95% confidence interval [CI]: -3.5, -1.4) AAPC -2.7% (95%CI: -4.3, -1.0). By town, most Chungbuk (AAPC: -23.7%; 95%CI: -30.2, -16.5) increased Gunwi-gun Gyeongbuk 3.0%; 1.1, 4.9). Over notable decline observed although exhibited disparities. To effectively achieve WHO hepatitis 2030, targeted interventions should prioritize persistent emerging prevalence.
Язык: Английский
Процитировано
0
Journal of Gastroenterology and Hepatology, Год журнала: 2025, Номер unknown
Опубликована: Май 1, 2025
ABSTRACT Background In an aging population, patients with chronic hepatitis B (CHB) may face a higher risk of osteopenia, osteoporosis, or fractures. We investigated the epidemiology and factors associated osteopenia osteoporosis in CHB. Methods This retrospective cohort study included ≥ 19 years who underwent bone mineral density (BMD) testing 2 times between 2005 2021 at Severance Hospital, Seoul, South Korea. Demographic comorbidities for without CHB were matched based on 1:4 ratio. Cox proportional hazard regression models used to estimate ratios assess risk. Results A total 275 7868 had normal BMD analyzed. The incidence was 25.8% 28.7%, respectively. After propensity score matching, second test, 73.8%, 24.7%, 1.5% 70.7%, 26.5%, 2.8% BMD, Risk these age, body mass index < 25, kidney disease, proton pump inhibitor use. There no significant differences cumulative Conclusions Patients showed similar risks osteoporosis. addition providing closer monitoring greater disease risk, further studies help understand that impact health.
Язык: Английский
Процитировано
0
The Lancet. Gastroenterology & hepatology, Год журнала: 2025, Номер unknown
Опубликована: Май 1, 2025
Язык: Английский
Процитировано
0
Clinical and Molecular Hepatology, Год журнала: 2024, Номер 30(4), С. 663 - 664
Опубликована: Июль 22, 2024
Язык: Английский
Процитировано
1
Clinical and Molecular Hepatology, Год журнала: 2024, Номер 30(4), С. 997 - 999
Опубликована: Июль 29, 2024
Язык: Английский
Процитировано
0